We are live on ! Find out more
OA

Oak Associates Portfolio holdings

AUM $1.49B
1-Year Est. Return 34.25%
This Fund
S&P 500
This Quarter Est. Return
-17.24%
1 Year Est. Return
+34.25%
3 Year Est. Return
+111.6%
5 Year Est. Return
+123.41%
10 Year Est. Return
+571.62%
AUM
$1.28B
AUM Growth
-$359M
Cap. Flow
-$60.5M
Cap. Flow %
-4.73%
Top 10 Hldgs %
43.57%
Holding
141
New
3
Increased
11
Reduced
53
Closed
12

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.34M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$1.33M
3
PFE icon
Pfizer
PFE
+$762K
4
PYPL icon
PayPal
PYPL
+$467K
5
MEDP icon
Medpace
MEDP
+$463K

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$7.62M
2
DKNG icon
DraftKings
DKNG
+$5.16M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$4.7M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$3.88M
5
EBAY icon
eBay
EBAY
+$3.76M

Sector Composition

Rank Sector Weight
1 Technology 41.48%
2 Healthcare 16.66%
3 Communication Services 14.06%
4 Consumer Discretionary 12.31%
5 Financials 11.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNT
76
DELISTED
Verint Systems
VRNT
$1.87M 0.15%
44,220
– –
COR icon
77
Cencora
COR
$60.3B
$1.86M 0.15%
13,184
-4,256
-24% -$651K
SYK icon
78
Stryker
SYK
$127B
$1.83M 0.14%
9,215
– –
AIT icon
79
Applied Industrial Technologies
AIT
$12.8B
$1.81M 0.14%
18,875
– –
VRTX icon
80
Vertex Pharmaceuticals
VRTX
$121B
$1.75M 0.14%
6,228
– –
MEDP icon
81
Medpace
MEDP
$16.8B
$1.69M 0.13%
11,296
+3,199
+40% +$463K
PRFT
82
DELISTED
Perficient Inc
PRFT
$1.69M 0.13%
18,417
– –
CNXC icon
83
Concentrix
CNXC
$1.36B
$1.63M 0.13%
12,000
– –
JNJ icon
84
Johnson & Johnson
JNJ
$635B
$1.62M 0.13%
9,143
-5
-0.1% -$891
FFIV icon
85
F5
FFIV
$22.1B
$1.61M 0.13%
10,525
– –
HUM icon
86
Humana
HUM
$46.7B
$1.47M 0.11%
3,130
– –
CRL icon
87
Charles River Laboratories
CRL
$10.9B
$1.34M 0.11%
6,284
– –
MRNA icon
88
Moderna
MRNA
$21.5B
$1.34M 0.1%
+9,393
New +$1.34M
MA icon
89
Mastercard
MA
$477B
$1.31M 0.1%
4,149
– –
TSLA icon
90
Tesla
TSLA
$1.24T
$1.31M 0.1%
5,817
– –
UI icon
91
Ubiquiti
UI
$31.8B
$1.28M 0.1%
5,162
-1,050
-17% -$279K
BIO icon
92
Bio-Rad Laboratories Class A
BIO
$8.42B
$1.27M 0.1%
+2,558
New +$1.33M
PCTY icon
93
Paylocity
PCTY
$6.71B
$1.26M 0.1%
7,220
– –
LRCX icon
94
Lam Research
LRCX
$382B
$1.19M 0.09%
27,850
– –
FTNT icon
95
Fortinet
FTNT
$112B
$1.18M 0.09%
20,800
– –
AMBA icon
96
Ambarella
AMBA
$2.99B
$1.13M 0.09%
17,306
– –
BIIB icon
97
Biogen
BIIB
$29.9B
$1.09M 0.09%
5,355
– –
CALX icon
98
Calix
CALX
$2.27B
$1.07M 0.08%
31,244
– –
CSGS
99
DELISTED
CSG Systems International
CSGS
$1.04M 0.08%
17,373
– –
SAIC icon
100
Saic
SAIC
$5.03B
$993K 0.08%
10,665
– –
2 3
4
5 6

Similar funds

FAT
First American Trust Santa Ana, California $1.49B AUM 21.98% 1-Year Est. Return
AIA
Ally Invest Advisors Charlotte, North Carolina $1.49B AUM 14.08% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.49B AUM 10.4% 1-Year Est. Return
PIM
Plato Investment Management Sydney, NSW, Australia $1.49B AUM 28.65% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RIM
Rush Island Management New York $1.49B AUM 4.65% 1-Year Est. Return
SB
Simmons Bank Pine Bluff, Arkansas $1.49B AUM 23.32% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $1.48B AUM 26.15% 1-Year Est. Return

Oak Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Oak Associates held 141 positions worth $1.28B, down 22% from $1.64B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Oak Associates withdrew a net $60.5M in Q2 2022, closing 12 positions and reducing 53 holdings. Its most notable exit was DraftKings, an estimated $5.16M position sold in full.

By sector, the portfolio is most concentrated in Technology at 41% of assets, down from 42% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Oak Associates opened a new position in Moderna worth $1.34M.

  • Oak Associates's largest Q2 2022 buy was Moderna: 9,393 shares worth $1.34M.
  • Oak Associates added most to Pfizer in Q2 2022, an estimated $762K increase.
  • Oak Associates's biggest Q2 2022 reduction was Apple, cutting an estimated $7.62M.
  • Oak Associates fully exited DraftKings in Q2 2022, selling an estimated $5.16M.
  • Oak Associates's ten largest holdings make up 44% of its $1.28B portfolio in Q2 2022.
  • Oak Associates opened 3 new positions and closed 12 in Q2 2022.
  • Oak Associates's portfolio value fell 22% quarter-over-quarter to $1.28B.

Based on Oak Associates's 13F filing for Q2 2022, filed 12 Aug 2022.